drugset / Trial / NCT01941615

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

NCT01941615

Phase 1 Terminated 18 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (FDV) on the multiple dose pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon®) in healthy premenopausal female volunteers.

Timeline

Start
2013-11
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Deleobuvir Small molecule Oral
Subject Faldaprevir Small molecule Oral
Subject Microgynon Unknown Oral

Indications

No indication recorded.